BLTE
Belite Bio, Inc
$147.33
-1.96%
2026-10-23
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Key Fundamentals
Forward P/E
74.04
EPS (TTM)
$-2.74
ROE
-22.1%
Profit Margin
0.0%
Debt/Equity
0.06
Price/Book
8.68
Beta
-1.24
Market Cap
$6.74B
Avg Volume (10D)
153K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$198.58
60D Low
$141.62
Avg Volume
182K
Latest Close
$147.33
Get breakout alerts for BLTE
Sign up for Breakout Scanner to receive daily notifications when BLTE triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Belite Bio, Inc (BLTE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BLTE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BLTE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.